A Study to Assess Anktiva in Patients With Long Covid-19.

Part of paid clinical trials in San Francisco, California.

Sponsor
ImmunityBio, Inc.
Study ID
NCT07108036
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • N-803 (IL-15 Superagonist) — DRUG
    N-803 administered subcutaneously.

Study Details

This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.

Key Dates

Start date
Nov 14, 2025
Status verified
Mar 2026
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: N-803
    All patients will be in this arm.

Primary Outcome Measure

Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration. [ Time Frame: Through 30 days post final study drug administration. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California - San FranciscoSan FranciscoCalifornia94110
Emily Fehrman
[email protected]
(650) 761-2163
Michael Peluso, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
University of California - San Francisco· San Francisco, CA

Related Studies